zs pharma acquired

The OncAlert Oral Cancer Risk Assessment System includes a rapid, point-of-care risk assessment test (OncAlert POC Test) and…, Japan’s Fujifilm Holdings Corp will acquire a drug making business from the U.S. based Biogen Inc for about $890 million. On 6 November it was reported that AstraZeneca had acquired ZS Pharma for US$2.7 billion. AstraZeneca announced today the successful completion of the tender offer for all of the outstanding shares of ZS Pharma (NASDAQ: ZSPH) and the subsequent acquisition of ZS Pharma as previously announced in November. You are about to access AstraZeneca historic archive material. SECTOR. Save. During his time at Alta, he led investments in SARcode Biosciences (acquired by Shire), Sonexa Therapeutics, Allakos, Lumena Pharmaceuticals and ZS Pharma. AstraZeneca said today it will acquire ZS Pharma for approximately $2.7 billion, in a deal designed to expand the buyer’s cardiovascular and metabolic disease portfolio. Under the terms of the agreement, AstraZeneca will acquire all of the outstanding capital stock of ZS Pharma for $90 per share in an all-cash transaction, or approximately $2.7 billion in aggregate transaction value. In connection with the merger, each outstanding share of ZS Pharma that was not accepted for payment in the tender offer (excluding shares held as treasury stock and any shares as to which appraisal rights have been validly exercised under Delaware law) were cancelled and converted into the right to receive $90.00 per share in cash, without interest and less any required withholding taxes, the same as the tender offer price. AstraZeneca has completed the acquisition of the entirety of Bristol-Myers Squibb’s interest in the companies’ diabetes alliance. AstraZeneca made the decision to acquire ZS Pharma in an effort to bolster its cardiometabolic disease offerings. AstraZeneca has completed its $2.7-billion acquisition of ZS Pharma, bolstering its cardiovascular and metabolic disease portfolio. ZS is a professional services firm that works side by side with companies to help develop and deliver products that drive customer value and company results. The transaction does not impact AstraZeneca’s financial guidance for 2015. ZS-9 complements the company’s increasing focus on CKD and CHF, including the investigational medicine roxadustat, which is currently in Phase III development for patients with anaemia associated with CKD, as well as its leading diabetes portfolio. Get the inside scoop on jobs, salaries, top office locations, and CEO insights. The deal will give AstraZeneca access to ZS Pharma's treatment for hyperkalemia, a condition of elevated potassium in the bloodstream that is associated with chronic kidney disease and chronic heart failure. Previously, Dr. Akkaraju served as a director on the Boards of Seattle Genetics, Principia Biopharma (acquired by Sanofi), Barrier Therapeutics (acquired by Stiefel Laboratories), Eyetech Pharmaceuticals (acquired by OSIP), ZS Pharma (acquired by AstraZeneca), Synageva Biopharma Corp. (acquired by Alexion Pharmaceuticals), Aravive, Inc., and Amarin Corporation. The drug joined AstraZeneca’s portfolio when the company acquired its original developer ZS Pharma in 2015 for $2.7 billion. The tender offer expired at 00:00 EST on 16 December 2015 and was not extended. Under the terms of the merger agreement, AstraZeneca will commence a tender offer to acquire all outstanding shares of ZS Pharma’s common stock. The approval is supported by data from the Phase III GRECO trial and the Phase I AMES trial. Prior to joining Adicet, Ms. Krehlik served in HR leadership roles across a variety of industries and with companies at various stages of growth. Summary. Alexander was CEO of ZS Pharma where he led the initial public offering and sale of ZS Pharma to AstraZeneca. ZS Pharma uses its proprietary ion­-trap technology to develop novel treatments for hyperkalaemia (high potassium levels), a serious condition of elevated potassium in the bloodstream, typically associated with chronic kidney disease (CKD) and chronic heart failure (CHF). LONDON — The British drug maker AstraZeneca said on Friday that it had agreed to acquire ZS Pharma, a California-based biopharmaceutical company, for $2.7 billion in cash. A submission for European Marketing Application Authorisation is also progressing as planned. Prior to joining Aimmune, Kevin was Vice President, Market Access and Commercial Development at ZS Pharma (acquired by AstraZeneca), where he was instrumental in launching Lokelma®, the company’s first therapeutic to treat hyperkalemia. He previously served on the boards of Lumena Pharmaceuticals, Inc. (acquired by Shire Plc), Otonomy, Inc. (IPO) and ZS Pharma, Inc. (acquired by AstraZeneca Plc). Our country sites can be located in the AZ Network. Prior to ZS Pharma, Dr. Alexander was a Director at Alta Partners, a venture capital firm, and was also Executive Chairman and interim CEO of SARcode Bioscience. Upon completion, ZS Pharma, which has around 200 employees across three sites in California, Texas and Colorado, will become a wholly owned subsidiary of AstraZeneca. ZS-9 is under regulatory review by the US Food and Drug Administration with a Prescription Drug User Fee Act goal date of 26 May 2016. AstraZeneca to acquire ZS Pharma for $90 per share Acquisition includes potential best-in-class hyperkalaemia treatment currently under US FDA regulatory review Acquisition expected to contribute Product Sales from 2016 and benefit AstraZeneca’s return to growth strategy Subject to customary conditions, including the tender of a majority of the outstanding ZS Pharma shares and the expiration or earlier termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, the transaction is expected to close by the end of 2015. ZS-9 is under regulatory review by the US Food and Drug Administration with a Prescription Drug User Fee Act goal date of 26 May 2016. Prior to joining Aimmune, Kevin was Vice President, Market Access and Commercial Development at ZS Pharma (acquired by AstraZeneca), where he was instrumental in launching Lokelma ®, the company’s first therapeutic to treat hyperkalemia. The transaction will give AstraZeneca access to the potassium-binding compound ZS-9, a potential best-in-class treatment for hyperkalaemia, a condition associated with increased mortality in CKD and CHF. All shares that were validly tendered and not withdrawn pursuant to the tender offer were accepted for payment today. Our patient-led strategy is focused on addressing the multiple risk factors facing CVMD and CKD patients at different stages of their disease, with the goal of reducing morbidity and mortality through life changing medicines. As of the expiration of the tender offer, a total of approximately 21,948,939 shares of ZS Pharma common stock were validly tendered and not withdrawn (excluding shares tendered pursuant to notices of guaranteed delivery for which certificates have not been delivered), representing approximately 86.6% of ZS Pharma’s outstanding shares. With this acquisition Fujifilm aims to accelerate the growth of its Bio CDMO business. The global development programme is being conducted by FibroGen in collaboration with AstraZeneca and Astellas. AstraZeneca is not responsible for the privacy policy of any third party websites. ZS-9 complements the Company’s increasing focus on CKD and CHF, including the investigational medicine roxadustat, which is currently in Phase III development for patients with anaemia associated with CKD, as well as its leading diabetes portfolio, a comorbidity often associated with CKD and CHF patients. ZS Pharma represents a strong fit with AstraZeneca’s pipeline and portfolio in Cardiovascular & Metabolic Disease, one of the company’s three main therapy areas. INDUSTRY. ZS Pharma acquired by AstraZeneca. Overview. Selina McKee. It is expected to generate Product Sales from 2016, with minimal earnings dilution over 2016 and 2017, becoming accretive to AstraZeneca’s core earnings from 2018. ZS Pharma was acquired by AstraZeneca for $2.7B on Nov 6, 2015. LONDON (AP) — Anglo-Swedish drug firm AstraZeneca has acquired U.S.-based biopharmaceutical company ZS Pharma in a deal worth $2.7 billion. Dr. McKearn holds a Ph.D. in Immunology from the University of Chicago and a Bachelor of Science (B.S.) Following completion of the merger, ZS Pharma’s shares ceased to be listed on NASDAQ, and ZS Pharma became a wholly owned subsidiary of AstraZeneca. In December the company announced its intention to acquire the respiratory portfolio of Takeda Pharmaceutical – namely Alvesco and Omnaris – for US$575 million [56] A day later, the company announced it had taken a 55% majority stake in Acerta for US$4 billion. The transaction strengthens AstraZeneca’s cardiovascular and metabolic disease (CVMD) portfolio with the addition of the potassium-binding compound ZS-9 (sodium zirconium cyclosilicate), a potential best-in-class treatment for hyperkalaemia, a condition associated with increased mortality in patients with chronic kidney disease (CKD), diabetes mellitus (DM), and chronic heart failure (CHF). Prior to ZS Pharma, Robert was a Director at Alta Partners, a venture capital firm located in San Francisco. I have read this warning and will not be using any of the contained product information for clinical purposes. Important notice for users After the acceptance of shares that were validly tendered and not withdrawn pursuant to the tender offer, AstraZeneca completed its acquisition of ZS Pharma through a merger of one of its subsidiaries with and into ZS Pharma. We look forward to welcoming the ZS Pharma team to AstraZeneca.”. ASTRAZENECA AND ZS PHARMA DISCLAIM ANY INTENT OR OBLIGATION TO UPDATE ANY FORWARD-LOOKING STATEMENTS AS A RESULT OF DEVELOPMENTS OCCURRING AFTER THE DATE HEREOF OR OTHERWISE. IF UNDERLYING ASSUMPTIONS PROVE INACCURATE OR UNKNOWN RISKS OR UNCERTAINTIES MATERIALIZE, ACTUAL RESULTS AND THE TIMING OF EVENTS MAY DIFFER MATERIALLY FROM THE RESULTS AND/OR TIMING DISCUSSED IN THE FORWARD-LOOKING STATEMENTS, AND YOU SHOULD NOT PLACE UNDUE RELIANCE ON THESE STATEMENTS. The largest life science acquisition in 2015 was Allergan - which was acquired by Allergan for $70.5B. Most recently she has served as chief commercial officer and a member of the executive team of ZS Pharma (acquired by AstraZeneca), where she led efforts to transition the company from the development stage to a commercial enterprise. For more information please visit: www.astrazeneca.com. The transaction is not subject to a financing condition. Operator of a biopharmaceutical company. The Board of Directors of ZS Pharma has unanimously approved the terms of the agreement. ZS Pharma, founded in 2008, is a privately held specialty pharmaceutical company based in Coppell, Texas and Menlo Park, CA. Life Science Company. Cardiovascular, metabolic disease and chronic kidney disease are key areas of focus for AstraZeneca as part of the company’s strategy for achieving scientific leadership and returning to growth. AZ completes acquisition of ZS Pharma. ZS Pharma (ZSPH) stock is spiking in late morning trading on Friday, after the biopharmaceutical company agreed to be acquired by AstraZeneca (AZN) for $2.7 billion.
Wie Schreibt Man Das Fußball Spielen, Sport Scheck Outlet Online, Preise Sansibar Sylt, Kleines Haus Im Schwarzwald Kaufen, Grundstück Kaufen Hockenheim, Biedermann Und Die Brandstifter, Edeka Quark Magerstufe, Ssv Markranstädt Tapfer, Designer Sale -80% Online, Dauer Der Regenzeit In Salah,